Updated antiemetic guidelines

1 Aug 2017 - 16:30

The American Society of Clinical Oncology (ASCO) recently published updated guidelines for the use of antiemetics in cancer patients receiving chemotherapy and radiation therapy.

Updates included recommending the addition of olanzapine for patients receiving highly emetogenic chemotherapy or experiencing breakthrough nausea and vomiting; administration of dexamethasone only on day 1 for patients on anthracycline and cyclophosphamide and adding a neurokinin 1 receptor antagonist (e.g. aprepitant) for patients on carboplatin where the AUC> 4mg/mL/min or high dose chemotherapy.

Certain recommendations were also amended for radiation-induced nausea and vomiting. Find the full guideline here.